Key result
Observational studies evaluating DOACs for venous thromboembolism yielded more favorable efficacy estimates than RCTs, including a 33% increase in prospective cohorts.
Why the study?
Randomized controlled trials face criticism for overselection, prompting encouragement of real-world cohort studies, but differences between RCTs and observational studies regarding populations and efficacy or safety results remained unclear.
Do observational studies overestimate the effectiveness and safety of DOACs compared to RCTs in patients with venous thromboembolism?
Systematic Review (n=276,092)
Do observational studies overestimate the effectiveness and safety of DOACs compared to RCTs in patients with venous thromboembolism?
Answers are grounded in this paper and cite their sources.
Observational studies may exaggerate treatment efficacy estimates of DOACs compared to RCTs in patients with venous thromboembolism, highlighting the need for cautious interpretation of real-world evidence.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Safieddine et al. (2020) conducted a systematic review in Venous thromboembolism (n=276,092). Direct oral anticoagulants (DOACs) vs. Conventional treatment was evaluated on Ratio of hazard ratios (RHR) comparing prospective cohort studies with RCTs for treatment efficacy (RHR 0.67, 95% CI 0.39-1.18). Observational studies evaluating DOACs for venous thromboembolism yielded more favorable efficacy estimates than RCTs, including a 33% increase in prospective cohorts.
Synapse has enriched 10 related papers. Consider them for comparative context: